192 related articles for article (PubMed ID: 11258591)
1. Preparing for the revolution--pharmacogenomics and the clinical lab.
Mehr IJ
Pharmacogenomics; 2000 Feb; 1(1):1-4. PubMed ID: 11258591
[TBL] [Abstract][Full Text] [Related]
2. DxS Ltd.
Little S
Pharmacogenomics; 2003 Jan; 4(1):97-101. PubMed ID: 12517290
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman R
Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics in Asia.
Tamaoki M; Gushima H; Tsutani K
Pharmacogenomics; 2004 Dec; 5(8):1023-7. PubMed ID: 15584872
[TBL] [Abstract][Full Text] [Related]
5. Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
Gibson N; Jawaid A; March R
Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553
[TBL] [Abstract][Full Text] [Related]
6. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
7. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
8. Awareness survey of parties involved in pharmacogenomics in Japan.
Tamaoki M; Gushima H; Tsutani K
Pharmacogenomics; 2007 Mar; 8(3):275-86. PubMed ID: 17324116
[TBL] [Abstract][Full Text] [Related]
9. Measuring the value of pharmacogenomics.
Phillips KA; Van Bebber SL
Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacogenomic approaches to clinical drug development.
Murphy MP
Pharmacogenomics; 2000 May; 1(2):115-23. PubMed ID: 11256585
[TBL] [Abstract][Full Text] [Related]
11. Evolution of pharmacogenomics.
Somogy A
Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
[TBL] [Abstract][Full Text] [Related]
12. Relevance of pharmacogenomics for developing countries in Europe.
Mitropoulos K; Johnson L; Vozikis A; Patrinos GP
Drug Metabol Drug Interact; 2011; 26(4):143-6. PubMed ID: 22017487
[TBL] [Abstract][Full Text] [Related]
13. Global pharmacogenomics: where is the research taking us?
Olivier C; Williams-Jones B
Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
[TBL] [Abstract][Full Text] [Related]
14. EPIDAUROS Biotechnologie AG.
Arnold HP; Kluge P; Mauch S
Pharmacogenomics; 2005 Jul; 6(5):535-8. PubMed ID: 16014003
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics: the implementation phase.
Sadee W
AAPS PharmSci; 2002; 4(2):E5. PubMed ID: 12141268
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics.
Nat Biotechnol; 2000 Oct; 18 Suppl():IT40-2. PubMed ID: 11221715
[No Abstract] [Full Text] [Related]
17. Clinical pharmacogenetics: how do we ensure a favorable future for patients?
Wiltshire T; Dong OM
Pharmacogenomics; 2018 Apr; 19(6):553-562. PubMed ID: 29620450
[TBL] [Abstract][Full Text] [Related]
18. [Perspectives on the current state of pharmacogenomics in drug development].
Tamaoki M
Yakugaku Zasshi; 2009 Jan; 129(1):135-45. PubMed ID: 19122441
[TBL] [Abstract][Full Text] [Related]
19. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
20. How molecular medicine transforms policy (and everything else).
Kean MA; Batchelder KF
J Biolaw Bus; 2004; 7(3):16-9. PubMed ID: 15460603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
